- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02914808
Oedema Study : Chroedem (CHROEDEM)
Assessment of Tissue and Biomolecular Complements of Lower Limb Chronic Oedema
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Chronic lower limb oedema is the consequence of an abnormal accumulation of fluid in the interstitium located beneath the skin of legs. It is a frequent disease with a significant morbidity (skin infections, leg ulcers…), which can deeply alter patient's quality of life.
On a pathological point of view, current main hypothesis is hemodynamic (i.e. failure of venous and lymphatic return).
Recent data suggest that other factors, particularly genetic ones (genes coding for proteins of inflammation or of fibrosis, for adipogenesis and for lymphangiogenesis…) could influence the development of CO. Stimulation of these mediators varies from one person to another and from one clinical setting to another (i.e. venous insufficiency vs. lymphedema etc…). One can therefore assume that CO is not a homogeneous entity and that the distribution of tissue components varies.
On a therapeutic point of view, this difference in the distribution of tissue components could at least in part explain the differences in effectiveness of compression therapy and in tissue dysmorphia from one person to another and from one type of CO to another.
The study primary objective is to assess and compare by MRI the different tissue components (oedema, fat, muscle, inflammation/fibrosis) of lower limb CO of venous vs. lymphatic origins.
The investigators shall conduct a prospective observational pilot study. 24 patients with a CO of PTS origin and 24 patients with a CO of lymphatic origin (primary lymphoedema) will undergo a clinical examination, 3-D laser scanner volumetry of their lower limbs, blood tests and a MRI of lower limb. Main exclusion criteria will be obesity and bilateral CO. The main primary outcome measure will be the proportion of fat, muscle and oedema assessed by MRI in a pre-determined lower limb area. The main secondary outcome measure will be the prevalence in each group of i) variations in exonic sequence of genes coding for proteins of inflammation/fibrosis, angiogenesis, adipogenesis; ii) variations in exonic sequence of genes reported in the literature as associated with primary lymphoedema.
This study should allow to better characterize tissue structure and inflammatory, adipous and angio-genetic profiles of lower limb CO. The potential therapeutic perspective is to adapt compressive therapies to the type of oedema and to test the impact of new therapies (e.g. anti-inflammatory drugs for oedema with important fibrotic component?).
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: ISABELLE QUERE, MD, PhD
- Phone Number: +33 (0)4 67 33 70 25
- Email: i-quere@chu-montpellier.fr
Study Locations
-
-
-
Montpellier, France, 34295
- Recruiting
- University hospital of Montpellier
-
Contact:
- ISABELLE QUERE, MD, PhD
- Phone Number: +33 (0)4 67 33 70 25
- Email: jp-galanaud@chu-montpellier.fr
-
Nîmes, France, 30
- Not yet recruiting
- University Hospital Nîmes
-
Contact:
- JEAN CHRISTOPHE JCG GRIS, MD PHD
-
-
Isère
-
Grenoble, Isère, France, 38700
- Not yet recruiting
- Pr Sophie BLAISE
-
Contact:
- Sophie BLAISE, PhD
- Phone Number: +33 (0)476765547
- Email: sblaise@chu-grenoble.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion criteria:
- Lower limb CO secondary to PTS or Primary lymphoedema (We will include secondary lymphedema of the lower limbs only if the matcing constraints on age and length of evolution do not allow pairing)
Exclusion criteria:
- Bilateral CO
- Obesity
- Mixed CO (PTS and lymphatic origins)
- CO of other origin : Heart failure, hepatic or renal impairment
- Denutrition
- Contra-indication to MRI
- Patient not affiliated to French Health Insurance System
- Patient protected by the law
- Patient refusing to participate
Study Plan
How is the study designed?
Design Details
- Observational Models: Other
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Proportion of fat muscle and oedema assessed by MRI in a pre determined lower limb area
Time Frame: 18 Months
|
18 Months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: ISABELLE QUERE, MD, PhD, University Hospital, Montpellier
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RECHMPL15_0489
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.